Orion Stock

Orion ROCE

The Return on Capital Employed (ROCE) of Orion (271560.KS) as of Aug 13, 2026 is 15.66 %. In the previous year, Return on Capital Employed (ROCE) was 17.20 % — a change of -8.97% (lower).

ROCE

15.66 %

YoY

-8.97%

Last updated:

In 2026, Orion's return on capital employed (ROCE) was 15.66 %, a -8.97% increase from the 17.20 % ROCE in the previous year.

Access this data via the Eulerpool API

Orion Stock analysis

What does Orion do? Orion Corp is a Finnish company that operates in the pharmaceutical industry. The company was founded in 1917 and is headquartered in Espoo, Finland. Orion Corp specializes in the development, manufacturing, and marketing of medications, as well as the diagnosis and treatment of diseases. As one of the leading pharmaceutical companies in Finland, Orion Corp is dedicated to researching and developing medications and medical devices to help doctors and their patients worldwide improve their quality of life. Orion Corp's business model focuses on selling prescription and over-the-counter medications, as well as manufacturing generic medications. Additionally, the company is involved in the diagnosis and treatment of diseases such as Parkinson's, cancer, and asthma. The company's main business is centered around three main divisions: pharmaceuticals, diagnostics, and animal health. Within these divisions, Orion Corp has various business areas. In the pharmaceutical division, the focus is on developing medications to combat Parkinson's, cancer, and asthma. The company has a strong product range of Parkinson's treatments that can alleviate symptoms and slow the progression of the disease. Furthermore, the company is involved in the development of cancer medications that can inhibit the growth of cancer cells. Orion Corp is also a key player in asthma treatment. The company produces medications that expand the airways and make breathing easier. In the diagnostics division, Orion Corp's main business is the development and manufacturing of diagnostic devices for diseases such as lung cancer and asthma, as well as products for monitoring blood sugar and cholesterol. Animal health is another important business area for Orion Corp. The company manufactures medications and accessories for animal health and offers a variety of products to veterinarians and breeders. These include, for example, animal vaccines or hormone preparations to increase fertility in animals. Orion's production facilities are located in six countries, including Finland, Germany, France, Russia, the USA, and India. Production within the company primarily takes place in Finland. In addition to manufacturing medications and medical devices, Orion Corp is also a leading producer and developer of raw materials and intermediates for pharmaceutical applications worldwide. In summary, Orion Corp offers a wide range of products and services in the health and animal health fields using the latest scientific knowledge and technologies. The company remains committed to continuously expanding its product and service portfolio and providing patients worldwide with high-quality and effective medications that positively impact their lives. Orion is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Orion's Return on Capital Employed (ROCE)

Orion's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Orion's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Orion's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Orion’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Orion stock

Return on Capital Employed (ROCE) of Orion is 15.66 % in 2026.

Return on Capital Employed (ROCE) of Orion changed from 17.20 % to 15.66 %, representing a -8.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Orion since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Orion with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — Orion

All Key Metrics — Orion